Abstract
In the UK, NICE uses cost-effectiveness analysis (CEA) to determine whether a technology will be reimbursed and provided within the NHS. However, CEA does not capture the impact of a new health technology on inequalities between population groups. Distributional cost-effectiveness analysis (DCEA), which is currently being explored in the NICE methods review, is an additional “layer” that can be added to a CEA model to include formal analysis within the decision making process.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
